The CH20993 strain of parainfluenza Type 1 virus used in this study was isolated ... and seventh days after inoculation were tested in human embryonic lung fibroblast (WI-38) tissue cultures ...

Modern laboratory techniques for the detection of novel human viruses are greatly needed as physicians and epidemiologists increasingly deal with infectious diseases caused by new or previously ...

CyanVac LLC, a clinical-stage biotechnology company developing intranasal vaccines using a transformational parainfluenza ...

Finding a cure for colds and the flu is tricky to say the least, but new science may help you prevent them or at least ...

Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored ...

As respiratory virus season peaks, it’s the time when catching a cold seems inevitable. The average adult gets two to three ...

It’s not like no one has tried. In the late ‘90s and early aughts, a now-defunct company, ViroPharma, developed an antiviral ...

These diseases are not only harmful and highly contagious but can also render entire farms or regions vulnerable to outbreaks. Importantly, the existence of viruses such as Bovine Parainfluenza Virus ...

Rational design of uncleaved prefusion-closed trimer vaccines for human respiratory syncytial virus and metapneumovirus. Nature Communications , 2024; 15 (1) DOI: 10.1038/s41467-024-54287-x Cite ...

Early results from 63 of the infants enrolled in the trial found the vaccine to be safe, tolerated and able to cut the chance ...